移民人群中人乳头瘤病毒疫苗接种的驱动因素及提高接种覆盖率的干预措施:系统综述与Meta分析
该系统综述与Meta分析检索2006年1月1日至2024年12月4日七个数据库及灰色文献,纳入117项研究、涉及16个国家和1个地区的5,638,838名参与者,评估移民HPV疫苗接种率及影响因素与推荐策略。女性移民合并接种率为23.0%(95%CI 10.0-44.0;I²=99.3%;n=7614),男性移民为21.0%(95%CI 5.0-58.0;I²=99.3%;n=2764),男女合并为17.0%(95%CI 8.0-33.0;I²=98.0%;n=3583)。
要点
- 女性移民HPV疫苗合并接种率为23.0%(95%CI 10.0-44.0;I²=99.3%;n=7614)。
- 男性移民合并接种率为21.0%(95%CI 5.0-58.0;I²=99.3%;n=2764)。
- 男女移民合并接种率为17.0%(95%CI 8.0-33.0;I²=98.0%;n=3583)。
核心结论
- 全球移民在HPV疫苗接种方面面临个体、家庭与社会、提供者及系统层面的多重障碍,导致接种率低和错过保护机会。
- 在许多低收入和中等收入国家,疫苗几乎不可获得或受种者需自费。
- 实现全生命周期普遍和公平免疫及宫颈癌消除目标,需通过多管齐下的策略解决这些障碍。
- 与移民社区合作共同开发满足其独特需求的有效定制交付模式至关重要。
研究设计与样本
- 系统综述与Meta分析,检索七个数据库及多个灰色文献来源,纳入2006年1月1日至2024年12月4日发表的任何语言研究。
- 纳入定性及定量横断面研究、队列研究和随机对照试验,聚焦第一代和第二代移民,排除国内移民研究。
- 共纳入117项研究,涉及16个国家和1个地区的5,638,838名参与者,其中933,189名为第一代和第二代移民。
- 采用WHO疫苗接种行为与社会驱动因素模型进行混合主题分析,并以随机效应Meta分析计算合并接种率估计值。
- 使用Joanna Briggs Institute清单评估偏倚风险,研究注册于PROSPERO(CRD42022347513)。
主要发现
- 女性移民HPV疫苗合并接种率为23.0%(95%CI 10.0-44.0;I²=99.3%;n=7614)。
- 男性移民合并接种率为21.0%(95%CI 5.0-58.0;I²=99.3%;n=2764)。
- 男女移民合并接种率为17.0%(95%CI 8.0-33.0;I²=98.0%;n=3583)。
- 79项(68%)研究为低偏倚风险,32项(27%)为中等风险,6项(5%)为高风险。
- 负向影响因素包括对疫苗安全性的担忧、文化信仰、对HPV疫苗或感染的不确定性和低知识水平、接触负面信息及缺乏卫生保健提供者推荐;实际障碍包括服务信息少、语言障碍、后勤挑战和疫苗高成本;促进因素包括对疫苗和卫生保健提供者的积极认知与信任、父母对青少年性活动的现实期望、责任感、卫生保健提供者推荐及社会网络支持。
关键数值与推荐
- 推荐的策略和干预包括针对不同目标群体(如父母或照护者及青少年)的文化敏感信息和定制沟通。
- 部署受信任的中介者(如同伴学校健康促进者、宗教倡导者和社区卫生工作者)是关键。
- 实施解决错过机会的实际解决方案(如将HPV疫苗接种与其他服务捆绑)、实施电子健康倡议、确保提供者强烈推荐、减少获取障碍(如通过免预约、移动和 outreach 服务)及加强疫苗接种监测系统。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: WHO's Cervical Cancer Elimination Initiative has set a target for 90% of girls to be fully vaccinated against human papillomavirus (HPV) by the age of 15 years by 2030, to substantially reduce deaths from cervical and other HPV-related cancers. However, progress has been slow, with only 27% global vaccine coverage in 2023. Migrants are an under-immunised group globally for many vaccine-preventable diseases, with data showing that they experience a high burden of HPV infection and widespread HPV under-immunisation. We aimed to identify drivers of HPV vaccine uptake in migrants, as well as assess uptake and explore recommended approaches, strategies, and best practices to promote uptake in migrant communities. METHODS: In this systematic review and meta-analysis, we searched seven databases and several grey literature sources for information published in any language between Jan 1, 2006, and Dec 4, 2024, on the drivers of HPV vaccine uptake among migrants globally. Defining migrants as foreign-born nationals, we included qualitative and quantitative cross-sectional studies, cohort studies, and randomised controlled trials focused on first-generation and second-generation migrants and excluded studies of internal migrants. Outcomes were frequency and percentage of HPV vaccine uptake; factors positively or negatively influencing uptake; and recommended approaches, strategies, and best practices to promote uptake as reported by study authors or participants. We conducted a hybrid thematic analysis using the WHO Behavioural and Social Drivers of Vaccination model to map drivers of uptake, and a random-effects meta-analysis to calculate pooled estimates of uptake. Risk of bias was assessed using Joanna Briggs Institute checklists. This study is registered with PROSPERO, CRD42022347513. FINDINGS: Of 3562 records returned by the search, 117 studies were included in the analysis, involving 5 638 838 participants across 16 countries and one territory, of whom 933 189 were first-generation and second-generation migrants. The pooled estimates of HPV vaccine uptake were 23·0% (95% CI 10·0-44·0; I2=99·3%; n=7614) among female migrants, 21·0% (5·0-58·0; I2=99·3%; n=2764) among male migrants, and 17·0% (8·0-33·0; I2=98·0%; n=3583) among male and female migrants combined. 79 (68%) studies were considered at low risk of bias, 32 (27%) were considered at moderate risk, and six (5%) were considered at high risk. Factors negatively influencing vaccine uptake included concerns about vaccine safety, cultural beliefs, uncertainty and low levels of knowledge about HPV vaccines or infection, exposure to negative information, and lack of recommendations from health-care providers. Practical barriers to uptake included little information on services, language barriers, logistical challenges, and the high cost of the vaccine. Enablers mainly included positive perceptions and trust in the vaccine and health-care providers, realistic expectations from parents regarding adolescents' sexual activity, a sense of responsibility, recommendations from health-care providers, and support from social networks. Recommended strategies and interventions to improve uptake included culturally sensitive messaging and tailored communication for different target groups (eg, parents or caregivers and adolescents). Deploying trusted mediators (eg, peer school health promoters, religious champions, and community health workers) was key, alongside implementing practical solutions to address missed opportunities (eg, bundling HPV vaccination with other services), implementing eHealth initiatives, ensuring strong provider recommendations, reducing access barriers (eg, through walk-in, mobile, and outreach services), and strengthening vaccination monitoring systems. INTERPRETATION: We show that migrants globally face complex individual, family and social, and provider-level and system-level barriers to HPV vaccination, resulting in low uptake of HPV vaccines and missed opportunities for protection. In many low-income and middle-income countries, there is little to no availability of vaccines and/or the recipient must pay for them. Achieving global commitments to universal and equitable immunisation across the life course-and making progress towards cervical cancer elimination-requires these barriers to be addressed through multipronged strategies. Collaborative efforts with migrant communities are essential to co-develop effective, tailored delivery models that meet their unique needs. FUNDING: The National Institute for Health and Care Research, the Academy of Medical Sciences, and the Medical Research Council.
引用
- Iwami M, Bouaddi O, Razai MS, et al. Drivers of human papillomavirus vaccine uptake in migrant populations and interventions to improve coverage: a systematic review and meta-analysis. Lancet Public Health. 2025. PMID: 40738554. doi:10.1016/S2468-2667(25)00148-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。